{{Distinguish|Forest Products Laboratory}}

{{Infobox company |
  name   = Forest Laboratories Inc. |
  logo   = [[Image:Forest Laboratories Logo.jpg]] |
  type   = [[Subsidiary]] |
  traded_as      = {{NYSE was|FRX}} |
  foundation     = {{start date and age|1954}} |
  parent        = [[Allergan, plc]] |
 subsid         = Furiex Pharmaceuticals |
  location       = [[New York City]], [[United States]] |
  key_people     = [[Brenton L. Saunders]] {{small|(CEO)}}|
  num_employees  = 5,600 |
  industry       = [[Pharmaceutical]]|
  revenue        = {{decrease}} [[US dollar|$]]3.1 billion (2013)<ref name=aboutfrx>{{cite web |url=http://news.frx.com/press-release/corporate-news/forest-laboratories-inc-reports-fiscal-year-fourth-quarter-2013-earning |title=Forest Laboratories, Inc. Reports Fiscal Year Fourth Quarter 2013 Earnings Per Share of $0.17 Including $0.08 Per Share of Acquisition Amortization |accessdate=2014-02-18}}</ref> |
  homepage       = http://www.frx.com
}}

'''Forest Laboratories''' was an [[United States|American]] [[pharmaceutical company]] headquartered in [[New York City]]. Forest Laboratories was known for licensing European pharmaceuticals for sale in the United States. The company had offices in [[St. Louis]], [[Cincinnati]], [[Jersey City]], [[Oakland]], [[Dublin]], [[Kent]] and [[Paris]].

==Corporate history==
In January 2014, Forest agreed to acquire [[Aptalis Pharma]] for $2.9 billion in order to gain access to treatments for [[gastrointestinal ailment]]s and [[cystic fibrosis]].<ref>{{cite news |url=https://www.bloomberg.com/news/2014-01-08/forest-agrees-to-acquire-aptalis-for-2-9-billion-in-cash.html|title=Forest to acquire Aptalis |accessdate=2013-01-08 | work=Bloomberg}}</ref>

In February 2014, [[Actavis]] announced it would acquire Forest Laboratories for around $25 billion.<ref>{{cite news|title= Actavis to buy Forest for $25 billion; windfall for investor Icahn |work= Reuters|date=18 Feb 2014|url= https://www.reuters.com/article/2014/02/19/us-actavis-forestlabs-idUSBREA1H0TI20140219|accessdate=20 Feb 2014 }}</ref>

In April 2014, Forest announced it would acquire Furiex Pharmaceuticals for $1 billion in cash.<ref>{{cite news|title= Forest to acquire Furiex |work= Reuters|date=28 April 2014|url= https://www.bloomberg.com/news/2014-04-28/forest-laboratories-to-acquire-furiex-for-1-1-billion-in-cash.html|accessdate=28 April 2014 }}</ref><ref>{{cite web|last=DEALBOOK|title=Forest Labs to Acquire Furiex Pharmaceuticals|url=https://dealbook.nytimes.com/2014/04/28/forest-labs-to-acquire-furiex-pharmaceuticals/|publisher=New York Times|accessdate=28 April 2014}}</ref>

On July 1, 2014, Actavis (now [[Allergan, Plc]], as of June 2015) completed its acquisition of Forest Laboratories. <ref>{{cite news|title= Actavis Completes Forest Laboratories Acquisition |date= 1 July 2014|url= http://www.allergan.com/NEWS/News/Thomson-Reuters/Actavis-Completes-Forest-Laboratories-Acquisition|accessdate=11 Apr 2016 }}</ref>

==Locations==
Both Lexapro and Namenda are produced in bulk at the Forest plant in Dublin, Ireland, with secondary processing, such as bottling and blister-packing, being carried out in the U.S. at plants in New York and St. Louis.

==Products==

Some of the products Forest Laboratories markets with its partners include:

* AeroBid ([[flunisolide]] inhaler) for [[allergic rhinitis]]
* Armour Thyroid ([[desiccated thyroid extract|thyroid]] tablets) for [[hypothyroidism]] and pituitary [[Thyroid-stimulating hormone|TSH]] suppression
* Bystolic ([[nebivolol]]) for [[hypertension]]
* Campral ([[acamprosate|acamprosate calcium]]) for maintenance of abstinence from alcohol in patients with [[alcohol dependence]]
* Celexa ([[citalopram|citalopram hydrobromide]]) for [[major depressive disorder|depression]] (developed by [[Lundbeck]])
* Cervidil ([[dinoprostone]] vaginal insert) for the initiation and/or continuation of cervical ripening in certain patients
* Combunox ([[oxycodone|oxycodone hydrochloride]]/[[ibuprofen]]) for the short-term management of acute moderate-to-severe pain
* Daliresp ([[roflumilast]]) for reduction of [[Chronic obstructive pulmonary disease|COPD]] exacerbations in patients with severe COPD
* Fetzima ([[levomilnacipran]] extended release) for depression
* Lexapro ([[escitalopram|escitalopram oxalate]]) for depression and [[generalized anxiety disorder]] (developed in cooperation with [[Lundbeck]])
* Levothroid ([[levothyroxine|levothyroxine sodium]]) for hypothyroidism and pituitary TSH suppression
* Linzess ([[linaclotide]]) for constipation-predominant [[irritable bowel syndrome]] and [[Functional constipation|chronic idiopathic constipation]]
* Monurol ([[fosfomycin|fosfomycin tromethamine]]) for certain [[urinary tract infection]]s
* Namenda and Namenda XR ([[memantine|memantine hydrochloride]]) for moderate-to-severe [[Alzheimer's disease]]
* Savella ([[milnacipran|milnacipran hydrochloride]]) for [[fibromyalgia]]
* [[Sudocrem]] medicated cream for [[irritant diaper dermatitis]]
* Teflaro ([[ceftaroline fosamil]]) for acute bacterial [[skin and skin structure infection]]s and [[community-acquired pneumonia]] caused by susceptible bacteria
* Tiazac ([[diltiazem|diltiazem hydrochloride]]) for hypertension and chronic stable [[angina pectoris]]
* Thyrolar ([[liotrix]]) for hypothyroidism and pituitary TSH suppression
* Tudorza Pressair ([[aclidinium bromide]] inhalation powder) for COPD
* Viibryd ([[vilazodone|vilazodone hydrochloride]]) for depression

==Controversies==
In September 2010, Forest Laboratories, Inc. and Forest Pharmaceuticals, Inc. (a subsidiary of Forest Laboratories) agreed to pay more than {{currency|313 million|USD}} to resolve allegations of civil and [[Strict liability (criminal)|criminal liability]] relating to [[felony]] [[obstruction of justice]] and the illegal distribution and promotion of pharmaceuticals, charges to which it [[plea|pled]] guilty.<ref>{{cite web |url=http://oig.hhs.gov/publications/docs/hcfac/hcfacreport2010.pdf |title=Health Care Fraud and Abuse Control Program, Annual Report for Fiscal Year 2010 |accessdate=2011-02-07 |page=19}}</ref> One of the pharmaceutical-related charges was a [[misdemeanor]] charge of illegally promoting the drugs [[Celexa]] and [[Lexapro]] for unapproved pediatric uses in treating [[Depression (clinical)#In children|depression]].<ref name=volkmann2010>{{cite news |first=Kelsey |last=Volkmann
 |url=http://www.bizjournals.com/cincinnati/stories/2010/09/13/daily36.html |accessdate=2011-04-10
 |title=Forest Pharmaceuticals to plead guilty, pay $313M, Business Courier, Cincinnati |date=2010-09-15}}</ref><ref name=noller2010/> The other drug-related charge was a misdemeanor charge of distributing the [[unapproved drug]] [[Levothroid]] in violation of the [[Federal Food, Drug, and Cosmetic Act|Food, Drug, and Cosmetic Act (FDCA)]].<ref name=volkmann2010/><ref name=noller2010/> Certain of the criminal activities were revealed with the help of [[whistleblower]]s, who were slated to receive {{currency|14 million|USD}} from the federal component of the settlement.<ref name=noller2010/>

=="Dodging taxes"==
On 13 May 2010, ABC news and Bloomberg business news reported that the organization "dodges taxes" by moving its profits offshore with the currently legal practice known as [[transfer pricing]]. U.S. Senator [[Carl Levin]] of Michigan has called transfer pricing "the corporate equivalent to secret offshore accounts of individual tax dodgers".<ref name=claiborne2011>{{cite web
 |first=Ron |last=Claiborne |url=http://abcnews.go.com/WN/us-firms-dodge-billions-taxes-moving-profits-overseas/story?id=10641219
 |title=U.S. Firms Dodge Billions in Taxes by Moving Profits Overseas |publisher=ABC World News |accessdate=2011-04-10
 |archiveurl=https://web.archive.org/web/20110220155750/http://abcnews.go.com/WN/us-firms-dodge-billions-taxes-moving-profits-overseas/story?id=10641219 |archivedate=2011-02-20
}}</ref>

==Pipeline candidates==
* [[Cariprazine]]
* Dutogliptin
* F2695

==Notes==
{{Reflist|2|refs=

<ref name=noller2010>{{Cite journal |last=Noller |first=Lisa M. |author2=Judith A. Waltz |date=December 2010 |title=Whistleblowers Take On Off-Label Marketing |periodical=[[Genetic Engineering & Biotechnology News]] |volume=30 |issue=21
 |page=11 }}</ref>

}}

==External links==
* [http://www.frx.com Forest Laboratories]
* [http://www.lexapro.com Lexapro]
* [http://www.namenda.com Namenda]
{{Pharmaceutical companies of the United States}}

[[Category:Manufacturing companies based in New York City]]
[[Category:Defunct pharmaceutical companies of the United States]]
[[Category:Companies formerly listed on the New York Stock Exchange]]
[[Category:Life sciences industry]]
[[Category:2014 acquisitions]]